AU2002253713B2 - Pharmaceutical composition comprising arsenite for the treatment of malignancy - Google Patents

Pharmaceutical composition comprising arsenite for the treatment of malignancy Download PDF

Info

Publication number
AU2002253713B2
AU2002253713B2 AU2002253713A AU2002253713A AU2002253713B2 AU 2002253713 B2 AU2002253713 B2 AU 2002253713B2 AU 2002253713 A AU2002253713 A AU 2002253713A AU 2002253713 A AU2002253713 A AU 2002253713A AU 2002253713 B2 AU2002253713 B2 AU 2002253713B2
Authority
AU
Australia
Prior art keywords
tumour
arsenite
treatment
malignancy
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002253713A
Other languages
English (en)
Other versions
AU2002253713A1 (en
Inventor
Bernardus Rademaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOMINOX Inc
Original Assignee
KOMINOX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29244880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002253713(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KOMINOX Inc filed Critical KOMINOX Inc
Publication of AU2002253713A1 publication Critical patent/AU2002253713A1/en
Assigned to KOMIPHARM INTERNATIONAL CO., LTD., YANG, YONG, LEE, SANG reassignment KOMIPHARM INTERNATIONAL CO., LTD. Request for Assignment Assignors: KOREA MICROBIOLOGICAL LABORATORIES, LTD, LEE, SANG, YANG, YONG
Assigned to KOMIPHARM INTERNATIONAL CO., LTD. reassignment KOMIPHARM INTERNATIONAL CO., LTD. Alteration of Name(s) of Applicant(s) under S113 Assignors: KOMIPHARM INTERNATIONAL CO., LTD., LEE, SANG BONG, YANG, YONG JIN
Application granted granted Critical
Publication of AU2002253713B2 publication Critical patent/AU2002253713B2/en
Priority to AU2008255139A priority Critical patent/AU2008255139B2/en
Assigned to KOMINOX, INC. reassignment KOMINOX, INC. Request for Assignment Assignors: KOMIPHARM INTERNATIONAL CO., LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002253713A 2002-04-10 2002-04-10 Pharmaceutical composition comprising arsenite for the treatment of malignancy Expired AU2002253713B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008255139A AU2008255139B2 (en) 2002-04-10 2008-12-04 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2002/000231 WO2003086424A1 (en) 2002-04-10 2002-04-10 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008255139A Division AU2008255139B2 (en) 2002-04-10 2008-12-04 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Publications (2)

Publication Number Publication Date
AU2002253713A1 AU2002253713A1 (en) 2003-10-27
AU2002253713B2 true AU2002253713B2 (en) 2008-09-18

Family

ID=29244880

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002253713A Expired AU2002253713B2 (en) 2002-04-10 2002-04-10 Pharmaceutical composition comprising arsenite for the treatment of malignancy
AU2008255139A Expired AU2008255139B2 (en) 2002-04-10 2008-12-04 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2008255139A Expired AU2008255139B2 (en) 2002-04-10 2008-12-04 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Country Status (25)

Country Link
US (1) US20050106262A1 (enExample)
EP (2) EP1496918B1 (enExample)
JP (1) JP2005525397A (enExample)
CN (1) CN1298332C (enExample)
AP (1) AP2004003167A0 (enExample)
AU (2) AU2002253713B2 (enExample)
BG (1) BG66356B1 (enExample)
BR (1) BR0215689A (enExample)
CA (1) CA2481602C (enExample)
CY (1) CY1114422T1 (enExample)
DK (2) DK2042182T3 (enExample)
EC (1) ECSP045408A (enExample)
ES (2) ES2944907T3 (enExample)
FI (1) FI1496918T3 (enExample)
HU (1) HU230851B1 (enExample)
IL (2) IL164470A0 (enExample)
LT (1) LT1496918T (enExample)
MX (1) MXPA04009898A (enExample)
NO (1) NO335317B1 (enExample)
NZ (1) NZ536452A (enExample)
PT (2) PT1496918T (enExample)
RO (1) RO123269B1 (enExample)
TN (1) TNSN04198A1 (enExample)
UA (1) UA80426C2 (enExample)
WO (1) WO2003086424A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024488A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20100249210A1 (en) * 2008-09-30 2010-09-30 Michael Bastiani Methods and compositions related to dlk-1 and the p38 mapk pathway in nerve regeneration
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
PL2475362T3 (pl) * 2009-09-10 2019-09-30 Kominox, Inc. Terapia celowana w nowotworowe komórki macierzyste i raka lekoopornego
RU2012108439A (ru) * 2009-09-18 2013-10-27 Коминокс, Инк. Способы лечения опухолей головного мозга
CN101695501B (zh) * 2009-10-10 2013-08-14 广汉恒宇新材料有限公司 一种纳米尺寸亚砷酸的壳聚糖包载体及其制造方法
CA3094115A1 (en) 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804928A1 (en) * 1994-02-18 1997-11-05 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
WO1999018798A1 (en) * 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1119152C (zh) * 1998-08-02 2003-08-27 哈尔滨医科大学第一临床医学院 治疗消化系统肿瘤注射液及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804928A1 (en) * 1994-02-18 1997-11-05 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
WO1999018798A1 (en) * 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kim et al Prostaglandins 1996; 51(6):413-425 *
Waxman, S. et al The Oncologist 2001; 6(2):3-10 *

Also Published As

Publication number Publication date
PT1496918T (pt) 2023-05-25
BG66356B1 (bg) 2013-09-30
CY1114422T1 (el) 2016-08-31
DK2042182T3 (da) 2013-08-26
DK1496918T3 (da) 2023-05-15
AU2008255139B2 (en) 2013-10-03
CN1625407A (zh) 2005-06-08
HUP0500199A2 (en) 2007-02-28
PT2042182E (pt) 2013-08-28
ES2944907T3 (es) 2023-06-27
EP1496918A1 (en) 2005-01-19
AP2004003167A0 (en) 2004-12-31
ECSP045408A (es) 2006-03-01
BR0215689A (pt) 2005-02-01
EP1496918B1 (en) 2023-02-08
NZ536452A (en) 2007-06-29
JP2005525397A (ja) 2005-08-25
IL164470A (en) 2010-12-30
CN1298332C (zh) 2007-02-07
BG108932A (en) 2005-11-30
TNSN04198A1 (en) 2007-03-12
WO2003086424A1 (en) 2003-10-23
RO123269B1 (ro) 2011-05-30
UA80426C2 (en) 2007-09-25
CA2481602C (en) 2011-06-21
ES2425418T3 (es) 2013-10-15
US20050106262A1 (en) 2005-05-19
AU2002253713A1 (en) 2003-10-27
EP2042182A1 (en) 2009-04-01
CA2481602A1 (en) 2003-10-23
LT1496918T (lt) 2023-05-25
NO20044573L (no) 2004-10-22
NO335317B1 (no) 2014-11-10
MXPA04009898A (es) 2005-06-20
FI1496918T3 (fi) 2023-05-11
IL164470A0 (en) 2005-12-18
AU2008255139A1 (en) 2009-01-08
HUP0500199A3 (en) 2008-03-28
EP2042182B1 (en) 2013-05-22
HU230851B1 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
AU2008255139A1 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
Li et al. The age of vanadium-based nanozymes: Synthesis, catalytic mechanisms, regulation and biomedical applications
WO1989000427A1 (fr) Utilisation pharmaceutique therapeutique d'un derive de glutathion
US9522164B2 (en) Disulfide chemotherapeutic agents and methods of use thereof
Joughi et al. Investigation on the antibacterial properties and rapid infected wound healing activity of silver/laterite/chitosan nanocomposites
Alvarez et al. Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer
Ehsani et al. Green fabrication of ZnO/magnetite-based nanocomposite-using Salvia officinalis extract with antibacterial properties enhanced infected full-thickness wound
KR100456831B1 (ko) 메타아르세나이트을 함유한 항암제 조성물
Gale et al. Further evaluation of diethyldithiocarbamate as an antagonist of cisplatin toxicity
AU2008258216A1 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
JPS6163619A (ja) 抗腫瘍剤、抗ウィルス剤
US11166908B2 (en) Composition for preparing an anti-tumour agent and a method for preparing an anti-tumour agent on the basis of same
Dharmalingam et al. Development of targeted magnetic bentonite nanocarrier for the delivery of 5-fluorouracil
ZA200408114B (en) Pharmaceutical compositions comprising arsenite for the treatment of malignancy
OA12802A (en) Pharmaceutical composition comprising arsenite forthe treatment of malignancy.
WO2002075007A2 (es) Metodo para hacer compuestos cupricos coloidales y sus usos
CN115025118A (zh) pH响应释放特性镓纳米药物与铂类化合物组合物在制备治疗耐药卵巢癌药物中的应用
Rojas et al. Interaction of radiosensitizers and WR-2721. I. Modification of skin radioprotection
Enikeeva et al. EFFICACY OF COLCHICINOL-2 IN MOUSE AND RAT TUMORS AND ITS OVERCOMING DRUG RESISTANCE
EP2068894A1 (en) Use of cis-rhenium (iii) diadamantate compounds for potentiating the antitumoral activity of platinium complexes

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: KOMIPHARM INTERNATIONAL CO., LTD.; LEE, SANG; YANG

Free format text: FORMER NAME: KOREA MICROBIOLOGICAL LABORATORIES, LTD; YANG, YONG; LEE, SANG

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ RADEMAKER, BERNARDUS

CB Opposition filed

Opponent name: LEE, S.

ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: OPPOSITION TO GRANT; REQUESTS UNDER SECTION 32; INVENTIVE CONCEPT; WHETHER PERSON WHO PROVIDES INPUT IS AN INVENTOR; WHETHER INVENTION SUBSEQUENTLY TRANSFERRED BY CONTRACT

Opponent name: SANG BONG LEE

Effective date: 20100817

PC1 Assignment before grant (sect. 113)

Owner name: KOMINOX, INC.

Free format text: FORMER APPLICANT(S): KOMIPHARM INTERNATIONAL CO., LTD.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired